{"type":"trials","record":{"id":41886,"source_id":"clinicaltrials-gov","external_id":"NCT05262244","title":"Targeted Fluorescence Imaging in AMD","brief_summary":"Rationale: To track performance of intravitreal distribution of anti-VEGF-A (Bevazicumab-800CW) and provide information about neovascularization and inflammation in Age-Related Macular Degeneration (AMD), thereby predicting progression and optimizing treatment Objective: To determine the safety and feasibility of fluorescence imaging of the eye with the fluorescent tracer bevacizumab-800CW for identification AMD with scanning laser angiography Study design: A non-randomized, non-blinded, prospective, single-center feasibility study. Study population: Patients group: patients with naïve wet AMD and wet AMD aged \\>60 years old with current treatment of anti-VEGF intravitreal. Control group: patients with naïve wet AMD and wet AMD aged \\>60 years old with current treatment of anti-VEGF intravitreal Intervention (if applicable): Intravenous injection of bevacizumab-800CW in the patient group. Main study parameters/endpoints: Safety and feasibility of the intravenous tracer bevacizumab-800CW in patients with naïve wet AMD and wet AMD by observing the uptake in retinal, choroid and neovascular tissue. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: No risk described in other (running) studies on intravenous injection with bevacizumab-800 CW. Patients need to come back 48-96 hours after injection and the eye measurements take about half an hour longer. There is no benefit with participation.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"University Medical Center Groningen","enrollment":12,"countries":["Netherlands"],"start_date":"2022-10-28","completion_date":"2024-03-30","last_update_date":"2024-12-06","source_url":"https://clinicaltrials.gov/study/NCT05262244","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"LEAF","age_range":"60 Years","comparator":null,"organization":"University Medical Center Groningen","interventions":["Bevacizumab-IRDye800CW"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety: number of participants with symptoms or changes in vital signs (blood pressure, heart rate and temperature) tha…","Feasibility: the possibility of measuring the specific uptake of fluorescence within the eye using both scanning laser…","Determination of the most optimal dose of bevacizumab-800CW for fluorescence imaging of the eye vascularization. — Dire…","Correlation of the fluorescence intensity, target-to-background ratio (TBR), with disease identification — Up to 1 year","Correlation between fluorescence intensity and clinical score — Up to 1 year","Correlation of VEGF expression within the tear fluid with the fluorescent signal — Up to 1 year"],"design_description":"NA · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","NAMD","Bevacizumab-IRDye800CW"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05262244","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-10-28 to 2024-03-30","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.887Z","intervention":["Bevacizumab-IRDye800CW"],"participants":12,"study_design":"NA · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety: number of participants with symptoms or changes in vital signs (blood pressure, heart rate and temperature) tha…","Feasibility: the possibility of measuring the specific uptake of fluorescence within the eye using both scanning laser…","Determination of the most optimal dose of bevacizumab-800CW for fluorescence imaging of the eye vascularization. — Dire…","Correlation of the fluorescence intensity, target-to-background ratio (TBR), with disease identification — Up to 1 year","Correlation between fluorescence intensity and clinical score — Up to 1 year","Correlation of VEGF expression within the tear fluid with the fluorescent signal — Up to 1 year"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41886","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}